This guideline provides comprehensive, evidence-based recommendations on prophylaxis, treatment, immunization, and drug interactions for a wide range of pediatric OIs—including new additions for coccidioidomycosis, hepatitis B revaccination, and updated immunization schedules—to guide clinicians caring for HIV‑exposed and infected children.
This guideline offers updated, evidence-based recommendations—from preconception through postpartum—on universal prenatal HIV testing, preferred antiretroviral regimens (e.g., bictegravir/TAF/FTC), maternal viral monitoring, obstetric management, and neonatal prophylaxis to further reduce perinatal HIV transmission toward elimination goals (defined as <1% transmission rate and <1 infection per 100,000 live births).
This guideline compiles up-to-date legal requirements across all U.S. states and territories, clarifying when healthcare providers and laboratories must report negative Hepatitis C test outcomes. It offers a clear, state-by-state breakdown to help public health entities and providers comply with surveillance obligations and improve data completeness.
This guideline presents a comprehensive state-by-state legal analysis of obligations for healthcare providers and laboratories to report negative HIV test outcomes. It clearly highlights jurisdictional differences, helping public health officials and clinicians ensure compliance with surveillance mandates and improve disease tracking.
This tool is intended to facilitate the calculation of the number of infections and other health outcomes averted, and the associated savings in direct medical costs and productivity costs, by STI prevention program activities as described in this User Guide and supporting scientific manuscript and appendix.
This fact sheet addresses common questions about insurance coverage for viral hepatitis prevention and treatment services. It outlines coverage details for hepatitis A and B vaccinations, hepatitis B and C screenings, and treatments across various insurance types, including Medicaid, Medicare, and private plans.
This guideline provides updated, evidence-based recommendations for diagnosing, treating, and managing latent tuberculosis infection (LTBI). It offers practical guidance for healthcare providers and public health programs, including testing options, treatment regimens, and considerations for special populations.
This guideline provides recommendations for HIV care teams on implementing long-acting injectable HIV treatment, including cabotegravir and rilpivirine.
This guideline outlines the Doxy-PEP Protocol for the prevention of certain sexually transmitted infections (STIs), specifically targeting syphilis, gonorrhea, and chlamydia, following potential exposure. It provides guidelines for healthcare providers on how to administer doxycycline as post-exposure prophylaxis (PEP), detailing protocols for prescription, timing, and patient education to reduce the risk of infection.
This guideline outlines the importance of Medicaid 1115 waivers and pre-release healthcare coverage in improving access to hepatitis C (HCV) treatment for incarcerated individuals. It discusses how expanding Medicaid coverage can enhance continuity of care, reduce transmission, and support reentry populations.
